AIMS/HYPOTHESIS: We examined whether analysis of lipids by ultra-performance liquid chromatography (UPLC) coupled to MS allows the development of a laboratory test for non-alcoholic fatty-liver disease (NAFLD), and how a lipid-profile biomarker compares with the prediction of NAFLD and liver-fat content based on routinely available clinical and laboratory data. METHODS: We analysed the concentrations of molecular lipids by UPLC-MS in blood samples of 679 well-characterised individuals in whom liver-fat content was measured using proton magnetic resonance spectroscopy ((1)H-MRS) or liver biopsy. The participants were divided into biomarker-discovery (n = 287) and validation (n = 392) groups to build and validate the diagnostic models, respectively. RESULTS: Individuals with NAFLD had increased triacylglycerols with low carbon number and double-bond content while lysophosphatidylcholines and ether phospholipids were diminished in those with NAFLD. A serum-lipid signature comprising three molecular lipids ('lipid triplet') was developed to estimate the percentage of liver fat. It had a sensitivity of 69.1% and specificity of 73.8% when applied for diagnosis of NAFLD in the validation series. The usefulness of the lipid triplet was demonstrated in a weight-loss intervention study. CONCLUSIONS/ INTERPRETATION: The liver-fat-biomarker signature based on molecular lipids may provide a non-invasive tool to diagnose NAFLD, in addition to highlighting lipid molecular pathways involved in the disease.
AIMS/HYPOTHESIS: We examined whether analysis of lipids by ultra-performance liquid chromatography (UPLC) coupled to MS allows the development of a laboratory test for non-alcoholic fatty-liver disease (NAFLD), and how a lipid-profile biomarker compares with the prediction of NAFLD and liver-fat content based on routinely available clinical and laboratory data. METHODS: We analysed the concentrations of molecular lipids by UPLC-MS in blood samples of 679 well-characterised individuals in whom liver-fat content was measured using proton magnetic resonance spectroscopy ((1)H-MRS) or liver biopsy. The participants were divided into biomarker-discovery (n = 287) and validation (n = 392) groups to build and validate the diagnostic models, respectively. RESULTS: Individuals with NAFLD had increased triacylglycerols with low carbon number and double-bond content while lysophosphatidylcholines and ether phospholipids were diminished in those with NAFLD. A serum-lipid signature comprising three molecular lipids ('lipid triplet') was developed to estimate the percentage of liver fat. It had a sensitivity of 69.1% and specificity of 73.8% when applied for diagnosis of NAFLD in the validation series. The usefulness of the lipid triplet was demonstrated in a weight-loss intervention study. CONCLUSIONS/ INTERPRETATION: The liver-fat-biomarker signature based on molecular lipids may provide a non-invasive tool to diagnose NAFLD, in addition to highlighting lipid molecular pathways involved in the disease.
Authors: Elisa Fabbrini; B Selma Mohammed; Faidon Magkos; Kevin M Korenblat; Bruce W Patterson; Samuel Klein Journal: Gastroenterology Date: 2007-11-28 Impact factor: 22.682
Authors: Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Jukka Westerbacka; Anna Kotronen; Barbara A Fielding; John Wahren; Leanne Hodson; Julia Perttilä; Tuulikki Seppänen-Laakso; Tapani Suortti; Johanna Arola; Rolf Hultcrantz; Sandra Castillo; Vesa M Olkkonen; Keith N Frayn; Matej Orešič; Hannele Yki-Järvinen Journal: Gastroenterology Date: 2010-06-27 Impact factor: 22.682
Authors: Leon A Adams; Oliver R Waters; Matthew W Knuiman; Robert R Elliott; John K Olynyk Journal: Am J Gastroenterol Date: 2009-03-17 Impact factor: 10.864
Authors: A Kotronen; V R Velagapudi; L Yetukuri; J Westerbacka; R Bergholm; K Ekroos; J Makkonen; M-R Taskinen; M Oresic; H Yki-Järvinen Journal: Diabetologia Date: 2009-02-13 Impact factor: 10.122
Authors: Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg Journal: Hepatology Date: 2008-02 Impact factor: 17.425
Authors: Santosh Lamichhane; Alex M Dickens; Partho Sen; Heikki Laurikainen; Faith Borgan; Jaana Suvisaari; Tuulia Hyötyläinen; Oliver Howes; Jarmo Hietala; Matej Orešič Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Isabel Bondia-Pons; Johanna Maukonen; Ismo Mattila; Aila Rissanen; Maria Saarela; Jaakko Kaprio; Antti Hakkarainen; Jesper Lundbom; Nina Lundbom; Tuulia Hyötyläinen; Kirsi H Pietiläinen; Matej Orešič Journal: FASEB J Date: 2014-05-20 Impact factor: 5.191